Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | LATS1 | O95835 | 1/20 | 0.31 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.31 |
| ▸ | ICMT | O60725 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4317261 | 0.86 | LOXL2 (0.38) | LOXL2TDP1L3MBTL1KDM6BKDM4C | |
| SCHEMBL6729852 | 0.81 | L3MBTL1 (0.36) | TDP1L3MBTL1KDM6BKDM4CCYP2D6 | |
| SCHEMBL1044868 | 0.79 | GAA (0.37) | TDP1L3MBTL1KDM6BKDM4CCYP2D6 | |
| SCHEMBL18865581 | 0.77 | TDP1 (0.33) | TDP1L3MBTL1KDM6BKDM4CCYP2D6 | |
| SCHEMBL28498139 | 0.77 | CA12 (0.35) | TDP1L3MBTL1CYP2D6CYP3A4CYP19A1 | |
| SCHEMBL4204738 | 0.76 | CYP2D6 (0.35) | TDP1L3MBTL1KDM6BKDM4CCYP2D6 | |
| SCHEMBL4816773 | 0.76 | KDM6B (0.33) | TDP1L3MBTL1KDM6BKDM4C | |
| SCHEMBL244894 | 0.75 | TDP1 (0.38) | TDP1L3MBTL1KDM6BKDM4CCYP2D6 | |
| SCHEMBL31558464 | 0.74 | SMN1; SMN2 (0.36) | TDP1L3MBTL1 | |
| SCHEMBL7505763 | 0.74 | SMN1; SMN2 (0.36) | TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621222-B | 6-6 Fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-3615537-B1 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | NOVARTIS AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| CN-110573511-B | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11458138-B2 | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | NOVARTIS AG (CH) | 2022-10-04 | — | — | US | disclosed |
| CN-114703144-A | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-114621222-A | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-2900657-B1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-03-11 | — | — | EP | disclosed |
| EP-3615537-A2 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | Novartis AG (CH) | 2020-03-04 | — | — | EP | disclosed |
| CN-110573511-A | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2019-12-13 | — | — | CN | disclosed |
| WO-2007039297-A1 | IMIDAZOPYRIDINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007017096-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-10-19 | — | — | US | disclosed |
| US-6969716-B2 | 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression | MERCK SHARP & DOHME LTD. | 2005-11-29 | — | — | US | disclosed |
| EP-1532120-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | disclosed |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | MERCK SHARP & DOHME, LTD. (GB) | 2004-09-30 | — | — | US | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| WO-2004014865-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | GABRA5, GABRA2, GABRA3 | LOXL2 3023/4885TDP1 1953/4885L3MBTL1 2983/4885 |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | LOXL2 2044/4885TDP1 2175/4885L3MBTL1 274/4885 |
| US-11458138-B2 | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | LATS1, LATS2, LSS | LOXL2 224/4885TDP1 2618/4885L3MBTL1 1726/4885 |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | LATS1, LATS2, LSS | LOXL2 224/4885TDP1 2618/4885L3MBTL1 1726/4885 |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | GABRA1, GABRA5, GABRA2 | LOXL2 1665/4885TDP1 2605/4885L3MBTL1 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.